Adamantane-Substituted Purines and Their β-Cyclodextrin Complexes: Synthesis and Biological Activity

Area of Science:

• Medicinal Chemistry
• Organic Chemistry
• Pharmacology

Background:

• Cyclin-dependent kinases (CDKs) are crucial regulators of the cell cycle.
• Synthetic 2,6,9-trisubstituted purines are investigated as potential anticancer drugs.
• These purine-based CDK inhibitors often suffer from poor water solubility.

Purpose of the Study:

• To enhance the physicochemical properties of purine-based CDK inhibitors.
• To explore the impact of adamantane moiety substitution on drug solubility and activity.
• To synthesize and characterize novel purine derivatives incorporating adamantane.

Main Methods:

• Synthesis of ten new purine derivatives with adamantane skeletons linked via phenylene spacers.
• Evaluation of biological activity, specifically inhibition of CDK2/cyclin E.
• Computational docking studies to analyze binding interactions.
• Assessment of the effect of beta-cyclodextrin on solubility and biological efficacy.

Main Results:

• Newly synthesized purine derivatives with adamantane moieties showed improved properties.
• The adamantane substitution did not negatively affect biological activity; some compounds exhibited enhanced CDK2/cyclin E inhibition.
• Docking studies revealed favorable non-polar interactions of the adamantane scaffold within the CDK2 binding pocket.
• Beta-cyclodextrin increased water solubility but reduced biochemical and cellular effects due to competitive binding.

Conclusions:

• Adamantane substitution is a viable strategy to improve the pharmaco-chemical profile of purine-based CDK inhibitors.
• Novel adamantane-purine derivatives maintain or enhance anticancer potential.
• While beta-cyclodextrin improves solubility, it may decrease therapeutic efficacy by hindering target engagement.